MUC16 and neoplasm: To better understand the potential use of serum CPT1A as a clinical biomarker, we further compared the predictive value and likelihood ratios of CPT1A with three conventional tumor markers, CA15–3, CEA, and CA125, in discrimination of breast cancer patients from healthy controls.